H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
Wainwright lifted the price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $32 from $30 on December 15, and reaffirmed a Buy rating on the stock. The firm told investors that the approval of Orladeyo in the pediatric patient population marks a significant factor for the rating update, as Orladeyo is the first and only targeted oral prophylactic therapy approved for use in patients ages two to 12 with hereditary angioedema. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) announced on December 12 that the FDA approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to Management further reported that the FDA granted approval to a capsule formulation of ORLADEYO for prophylaxis for the prevention of HAE attacks in adult and pediatric patients 12 years and older in December 2020, which now holds approval in over 45 countries across the
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]Yahoo! Finance
- BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 YearsGlobeNewswire
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BCRX
Earnings
- 11/3/25 - Beat
BCRX
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- BCRX's page on the SEC website